These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 3210296)

  • 21. [Clinical laboratory approach to evaluate administration dose of arbekacin. Reevaluation of in vitro MIC break points in the disk susceptibility test].
    Matsuo K; Uete T
    Jpn J Antibiot; 1994 Aug; 47(8):1041-52. PubMed ID: 7933533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field].
    Motohiro T; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Fujimoto T; Nishiyama T; Ishimoto K; Tominaga K
    Jpn J Antibiot; 1984 Oct; 37(10):1898-918. PubMed ID: 6094868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of in vitro antimicrobial activity of cefazolin alone and in combination with cefmetazole or flomoxef using agar dilution method and disk diffusion method].
    Matsuo K; Uete T
    Jpn J Antibiot; 1992 Oct; 45(10):1253-66. PubMed ID: 1479676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical laboratory approach for estimating effective administrative dose of tobramycin. Reevaluation of in vitro MIC break points of disk susceptibility test].
    Uete G; Matsuo K; Uete T
    Jpn J Antibiot; 1989 Sep; 42(9):1888-99. PubMed ID: 2810752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Laboratory and clinical studies of sulbactam/cefoperazone in the pediatric field].
    Nishimura T; Tabuki K; Takashima T; Takagi M
    Jpn J Antibiot; 1984 Oct; 37(10):1880-92. PubMed ID: 6094866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical laboratory approach for estimating effective administrative dose of cefsulodin].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 Sep; 37(9):1652-60. PubMed ID: 6439909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bacteriological, pharmacokinetic and clinical studies on sulbactam/cefoperazone in the pediatric field].
    Fujii R; Meguro H; Arimasu O; Mashiko J; Tajima T; Nonaka C; Nagamatsu I; Sato Y; Honjo T; Watanabe A
    Jpn J Antibiot; 1984 Dec; 37(12):2427-56. PubMed ID: 6098739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1990 Apr; 43(4):636-58. PubMed ID: 2199689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evaluation of sulbactam/cefoperazone in lower respiratory tract infections].
    Ishibashi T; Takamoto M; Shinoda A; Yoshida M; Ichikawa Y; Kido M; Ninomiya K; Kitahara Y; Hara N; Tsurutani H
    Jpn J Antibiot; 1990 Feb; 43(2):239-56. PubMed ID: 2194054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transfer of injected sulbactam/cefoperazone into burn blister fluid].
    Aoyama H; Sugiyama H; Tada M; Okuda J; Izawa Y
    Jpn J Antibiot; 1988 Sep; 41(9):1279-84. PubMed ID: 3241326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Basic and clinical studies on tazobactam/piperacillin in pediatric field].
    Motohiro T; Nagai K; Yamada T; Oki S; Yamada T; Yoshinaga Y; Tsumura N; Oda K; Sakata Y; Kato H; Imai S; Morita J; Matsuo Y; Ikezawa S; Takahgashi K; Fukuda T; Yamashita Y; Aramaki M; Hayashi M; Yamakawa R; Ono-E ; Tananari Y; Tsutsumi T; Hoshuyama A; Aida K
    Jpn J Antibiot; 1998 Jun; 51(6):413-31. PubMed ID: 9755831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Enhancement of susceptibility of sulbactam/cefoperazone-treated bacteria to phagocytes].
    Tanaka T; Iida-Tanaka K; Irino S
    Jpn J Antibiot; 1991 Jul; 44(7):732-5. PubMed ID: 1886199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical studies on sulbactam/cefoperazone in the field of obstetrics and gynecology].
    Obata I; Ryu F; Imagawa N; Ochiai K; Koike K; Morimoto O; Hachiya S
    Jpn J Antibiot; 1984 Dec; 37(12):2478-94. PubMed ID: 6098741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1991 Feb; 44(2):130-9. PubMed ID: 2041154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fundamental and clinical studies of sulbactam/cefoperazone in the field of pediatrics].
    Nakazawa S; Sato H; Narita A; Nakazawa S; Suzuki H; Chikaoka H; Tazoe K
    Jpn J Antibiot; 1984 Nov; 37(11):2174-87. PubMed ID: 6098710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diffusion of sulbactam and cefoperazone into the prostatic tissue].
    Okamura K; Hashimoto H; Morikawa M; Saga Y; Nishimoto M; Yachiku S; Osani H; Yamauchi K
    Hinyokika Kiyo; 1989 Apr; 35(4):727-34. PubMed ID: 2735275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Enhancement of in vitro antimicrobial activity of cefmetazole and cefotiam in combination against methicillin-susceptible and -resistant Staphylococcus aureus studied using checkerboard MIC method and disc diffusion method with discs containing both drugs].
    Matsuo K; Uete T
    Jpn J Antibiot; 1993 Mar; 46(3):222-33. PubMed ID: 8510319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro antibacterial activity of cefoperazone-sulbactam].
    Zhang Y; Zhang J; Zhou L
    Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):676-9. PubMed ID: 8731829
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Xiao S; Zhuo C; Zhuo C
    Comput Math Methods Med; 2021; 2021():1175379. PubMed ID: 34868336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.